Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Stopped early · Phase 2

Conditions studied: Aspergillosis

In brief

The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.

Key facts

Study ID

NCT00047827

Run by

Astellas Pharma Inc

People needed

2

Starts

2002-12-01

Expected to finish

2003-02-01

Last updated by the study team

2014-08-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have proven or probable systemic infection with Aspergillus species and have received no more than 96 hours of prior therapeutic doses of systemic antifungal therapy

You may not qualify if…

• Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal
• Has allergic bronchopulmonary aspergillosis, aspergillomas, or with sinus aspergillosis or external otitis who do not have evidence of tissue invasion
• Has life expectancy of less than five days

Where it is running

• Study site — Washington D.C., District of Columbia, United States
• Study site — Atlanta, Georgia, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Detroit, Michigan, United States
• Study site — St Louis, Missouri, United States
• Study site — Memphis, Tennessee, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.